These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26116314)

  • 21. Recent advances in Parkinson's disease.
    Vécsei L
    Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
    [No Abstract]   [Full Text] [Related]  

  • 22. The six gaps in the search of neuroprotection for Parkinson's disease.
    Espay AJ; Fasano A; Morgante F
    Expert Rev Neurother; 2012 Feb; 12(2):111-3. PubMed ID: 22288665
    [No Abstract]   [Full Text] [Related]  

  • 23. Neuroprotection for Parkinson's disease: a call for clinically driven experimental design.
    Bezard E
    Lancet Neurol; 2003 Jul; 2(7):393. PubMed ID: 12849115
    [No Abstract]   [Full Text] [Related]  

  • 24. Trial designs used to study neuroprotective therapy in Parkinson's disease.
    Lang AE; Melamed E; Poewe W; Rascol O
    Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disease-modifying drugs and Parkinson's disease.
    Allain H; Bentué-Ferrer D; Akwa Y
    Prog Neurobiol; 2008 Jan; 84(1):25-39. PubMed ID: 18037225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are dopamine receptor agonists neuroprotective in Parkinson's disease?
    Le WD; Jankovic J
    Drugs Aging; 2001; 18(6):389-96. PubMed ID: 11419913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, immunocytochemistry evaluation, and molecular docking investigation of several 4-aminopyridine derivatives as potential neuroprotective agents for treating Parkinson's disease.
    Li S; Wei D; Mao Z; Chen L; Yan X; Li Y; Dong S; Wang D
    Bioorg Chem; 2017 Aug; 73():63-75. PubMed ID: 28618343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible neuroprotective therapy for Parkinson's disease.
    Ogawa N
    Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis.
    Offen D; Hochman A; Gorodin S; Ziv I; Shirvan A; Barzilai A; Melamed E
    Adv Neurol; 1999; 80():265-9. PubMed ID: 10410731
    [No Abstract]   [Full Text] [Related]  

  • 30. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.
    Youdim MB; Grünblatt E; Levites-Royak Y; Mandel S
    Adv Neurol; 2001; 86():115-24. PubMed ID: 11553968
    [No Abstract]   [Full Text] [Related]  

  • 31. Discovering neuroprotection in Parkinson's disease, or getting to haphazard.
    Kieburtz K
    Mt Sinai J Med; 2010; 77(6):700-6. PubMed ID: 21105130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 33. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats.
    Jin F; Wu Q; Lu YF; Gong QH; Shi JS
    Eur J Pharmacol; 2008 Dec; 600(1-3):78-82. PubMed ID: 18940189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nicotine neuroprotection against nigrostriatal damage: importance of the animal model.
    Quik M; O'Neill M; Perez XA
    Trends Pharmacol Sci; 2007 May; 28(5):229-35. PubMed ID: 17412429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease.
    Ebadi M; Sharma S; Muralikrishnan D; Shavali S; Eken J; Sangchot P; Chetsawang B; Brekke L
    Proc West Pharmacol Soc; 2002; 45():36-8. PubMed ID: 12434520
    [No Abstract]   [Full Text] [Related]  

  • 37. Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.
    Swart T; Hurley MJ
    CNS Drugs; 2016 Dec; 30(12):1127-1135. PubMed ID: 27826740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alpha-2 adrenergic receptors and Parkinson's disease].
    Bonnet AM
    Presse Med; 2002 Jul; 31(25):1193-5. PubMed ID: 12192732
    [No Abstract]   [Full Text] [Related]  

  • 39. Carvacrol promotes neuroprotection in the mouse hemiparkinsonian model.
    Dati LM; Ulrich H; Real CC; Feng ZP; Sun HS; Britto LR
    Neuroscience; 2017 Jul; 356():176-181. PubMed ID: 28526576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings].
    Rákóczi K; Klivényi P; Vécsei L
    Ideggyogy Sz; 2009 Jan; 62(1-2):25-34. PubMed ID: 19248724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.